Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Immunotherapy has become an important treatment for cancer in recent years. PD-L1 and PD-1 inhibitors are the first-line treatments for advanced NSCLC lacking driver mutations. Although both PD-L1 and PD-1 inhibitors are effective, systematic reviews have reported differences in their clinical performance, and increasing numbers of studies on ICIs are being reported.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
